Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.6676
-0.0022 (-0.33%)
At close: Apr 2, 2025, 4:00 PM
0.6590
-0.0086 (-1.29%)
After-hours: Apr 2, 2025, 6:53 PM EDT
Palisade Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
2.94M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PALI News
- 19 days ago - Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewsWire
- 21 days ago - Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - GlobeNewsWire
- 4 weeks ago - Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 5 weeks ago - Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - GlobeNewsWire
- 6 weeks ago - Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 7 weeks ago - Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire
- 2 months ago - Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - GlobeNewsWire
- 3 months ago - Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire